Suppr超能文献

子宫肉瘤:来自单一机构的回顾性研究。

Uterine Sarcoma: Retrospective Study From A Single institute.

作者信息

Suchetha S, Vijayashanti T, Rema P, Sivaranjith J, Kumar Aswin, Krishna K M Jagathnath, James Francis V

机构信息

Division of Gynaecologic Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala India.

Division of Surgical Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala India.

出版信息

J Obstet Gynaecol India. 2022 Aug;72(Suppl 1):306-312. doi: 10.1007/s13224-021-01612-9. Epub 2022 Feb 23.

Abstract

ABSTRACT

Uterine sarcomas are heterogeneous group of tumours comprising 1% of gynaecological malignancies. There is lack of concences on optimal treatment of uterine sarcomas. This is because of lack of randomised controlled trials due to rarity of these tumours. Surgical management without spill remains the standard primary treatment. Most of the times uterine sarcomas are diagnosed postoperatively from histopathology report of either myomectomy or hysterectomy. This retrospective study analysed the clinico pathological characteristics, prognostic factors, treatment details and survival outcome of different types of uterine sarcomas.

MATERIALS AND METHODS

This is a retrospective analysis of 59 patients of uterine sarcomas. All patients underwent surgery. Adjuvant chemotherapy or radiation treatment were given according to histopathological report and FIGO stage. Patients were followed up every three months for first two years and then every six months. Disease free survival (DFS) and Overall survival (OS) were calculated.

STATISTICAL ANALYSIS

The data were summarized using descriptive statistics as mean, percent and range. Survival probabilities were estimated using Kaplan-Meier method and the significance of difference between the survival curves were calculate using log-rank test.

RESULTS

Uterine sarcomas are rare and aggressive tumours of uterus. Majority of these tumours present in early stage. Surgery remains the main treatment modality. Role of adjuvant radiation treatment remains controversial. Tumour stage is the most important prognostic factor.

摘要

摘要

子宫肉瘤是一组异质性肿瘤,占妇科恶性肿瘤的1%。对于子宫肉瘤的最佳治疗方法尚无共识。这是因为这些肿瘤罕见,缺乏随机对照试验。无瘤手术仍然是标准的主要治疗方法。大多数情况下,子宫肉瘤是在肌层切除术或子宫切除术后根据组织病理学报告确诊的。这项回顾性研究分析了不同类型子宫肉瘤的临床病理特征、预后因素、治疗细节和生存结果。

材料与方法

这是一项对59例子宫肉瘤患者的回顾性分析。所有患者均接受了手术。根据组织病理学报告和国际妇产科联盟(FIGO)分期给予辅助化疗或放疗。患者在头两年每三个月随访一次,之后每六个月随访一次。计算无病生存期(DFS)和总生存期(OS)。

统计分析

数据采用描述性统计方法进行汇总,以均值、百分比和范围表示。使用Kaplan-Meier方法估计生存概率,并使用对数秩检验计算生存曲线之间差异的显著性。

结果

子宫肉瘤是子宫罕见且侵袭性强的肿瘤。这些肿瘤大多在早期出现。手术仍然是主要的治疗方式。辅助放疗的作用仍存在争议。肿瘤分期是最重要的预后因素。

相似文献

1
Uterine Sarcoma: Retrospective Study From A Single institute.
J Obstet Gynaecol India. 2022 Aug;72(Suppl 1):306-312. doi: 10.1007/s13224-021-01612-9. Epub 2022 Feb 23.
2
[Uterine sarcomas: clinical and histopathological aspects. Report on 15 cases].
Gynecol Obstet Fertil. 2008 Jun;36(6):628-35. doi: 10.1016/j.gyobfe.2008.03.012. Epub 2008 Jun 5.
4
Diagnosis and surgical therapy of uterine sarcoma.
Acta Chir Iugosl. 2006;53(3):67-72. doi: 10.2298/aci0603067v.
5
6
Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up.
Int J Gynecol Cancer. 2004 Jul-Aug;14(4):659-64. doi: 10.1111/j.1048-891X.2004.14420.x.
7
Prognostic factors associated with uterine sarcomas: the experience of a single institution.
J Obstet Gynaecol. 2019 Feb;39(2):231-236. doi: 10.1080/01443615.2018.1492529. Epub 2018 Oct 24.
9
The retrospective analysis of patients with uterine sarcomas: A single-center experience.
J Cancer Res Ther. 2016 Jan-Mar;12(1):309-13. doi: 10.4103/0973-1482.148698.

引用本文的文献

1
Orosomucoid 1 is a Potential Prognostic Biomarker for Uterine Sarcoma.
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251343487. doi: 10.1177/15330338251343487. Epub 2025 May 19.
3
Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma.
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241245924. doi: 10.1177/15330338241245924.

本文引用的文献

1
Prognostic factors, survival outcomes, and surgical practices when dealing with uterine sarcomas: 8 years’ clinical experience.
J Turk Ger Gynecol Assoc. 2019 Aug 28;20(3):154-164. doi: 10.4274/jtgga.galenos.2019.2019.0061. Epub 2019 Jul 12.
2
Uterine sarcomas.
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:51-58. doi: 10.1002/ijgo.12613.
3
Uterine sarcoma - current perspectives.
Int J Womens Health. 2017 Aug 31;9:597-606. doi: 10.2147/IJWH.S117754. eCollection 2017.
4
A Multicentre Retrospective Review of Clinical Characteristics of Uterine Sarcoma.
J Obstet Gynaecol Can. 2017 Aug;39(8):652-658. doi: 10.1016/j.jogc.2017.03.090.
6
Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
Asian Pac J Cancer Prev. 2016;17(4):1759-67. doi: 10.7314/apjcp.2016.17.4.1759.
7
Uterine Sarcoma: Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database.
Int J Gynecol Cancer. 2016 Jul;26(6):1098-104. doi: 10.1097/IGC.0000000000000720.
8
Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications.
Obstet Gynecol. 2016 Mar;127(3):468-473. doi: 10.1097/AOG.0000000000001242.
9
Uterine sarcomas.
Int J Gynaecol Obstet. 2015 Oct;131 Suppl 2:S105-10. doi: 10.1016/j.ijgo.2015.06.006.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验